[eng] Utility Theory and Health Status measurement: the Debate QALYs vs HYEs . by Claude Le Pen . A vigorous debate has recently opposed int the field on the economic assessment of medical technologies two methods to value health states : the "Quality Adjusted Life Years" (QALYs) and the...

An overview of the present state of development of pharmacoeconomics in France is given, and more specifically how it works, in what context it operates, what kind of studies it produces, what kind of results it reaches, and what kind of future it may expect. The main features of the French...

EPO markets have proven to be highly country-specific. EPO market sizes, EPO retail/hospital distribution mixes and BIOSIM-EPO/REF price differences may not be determining factors of BIOSIM-EPO uptakes. Prescription and substitution incentives to use BIOSIM-EPO appear to be determining factors...

Objective: To describe the economic impact of age-related macular degeneration (AMD) and to assess its medical and non-medical costs. Design and settings: An observational study was carried out in 105 patients in two French centres in a sample of 105 French patients. All consecutive patients,...

The availability of the Diagnosis Related Group (DRG) system for determining hospital costs in some European countries has encouraged its use in pharmacoeconomic evaluations. The DRG system was developed in the US to provide data for prospective payments for hospitals. However, the financing of...

Objective: To assess the relationship between severity and progression of illness in Parkinson's disease and the use of healthcare resources. Design and setting: This was a prospective cost-of-illness study conducted in France based on clinical observation over a 6-month period of patients with...

Objective: The objective of the study was to compute a cost-effectiveness ratio relating the economic cost of trandolapril to the number of effectiveness units (i.e. life-years) gained. Design and Setting: The trandolapril cardiac evaluation (TRACE) study was a prospective placebo-controlled...

Objective: Cost is an issue when prescribing two drugs with equivalent efficacy. We compared the direct medical costs of topical brinzolamide 1% (twice a day or three times daily) with topical dorzolamide 2% (twice a day or three times daily) in France, Italy, Portugal and Spain in patients with...